nOPV2

BIOLOGICAL4 trials

Sponsors

Fidec Corporation, PATH

Conditions

PolioPoliomyelitis

Phase 3

A phase 3, double-blind, randomized, controlled trial to assess the safety of a novel type 2 oral polio vaccine (nOPV2) in infants and young children and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia

Active, not recruitingPACTR202010705577776

Start: 2021-01-04Target: 2945Updated: 2026-08-03

Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants

CompletedNCT05033561

Fidec CorporationPoliomyelitis

Start: 2021-12-16End: 2022-10-25Updated: 2024-08-23

A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants

RecruitingNCT07010822

Fidec CorporationPoliomyelitis

Start: 2026-04-30End: 2027-03-08Target: 740Updated: 2026-09-09

Phase 4

A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2

CompletedNCT05677256

Fidec CorporationPoliomyelitis

Start: 2023-11-09End: 2024-08-25Updated: 2026-09-03

Related Papers

Effect of inactivated poliovirus vaccine on nasal mucosal immunity and pharyngeal shedding following novel oral poliovirus vaccine type 2 challenge: A randomized, open-label trial.

PubMed2026-08-18

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

2024-02-2213 citations

Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.

2023-12-154 citations

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.

2020-12-0963 citations